PEGylation
- FDA Approved PEGylated Drugs By 2025
- Monodisperse (Discrete) PEGylation vs. Polydisperse PEGylation: Future Trends
- FDA Approves Palopegteriparatide for Hypoparathyroidism
- PEG‐rhG‐CSF for Neutropenia
- PEGylated Liposomes in the Clinic and Clinical Trials
- PEG-Interleukin-2 (PEG-IL-2) Therapeutics in Cancer
- Long Acting PEGylated Interferon: Application of PEG
- PEG G-CSF With Prolonged Biological Activity
- Potential Limitations of PEGylated Therapeutic Proteins
- The Applications of PEGylation Reagents